Skip Navigation


Carcinogenesis Advance Access originally published online on February 17, 2005
Carcinogenesis 2005 26(6):1091-1099; doi:10.1093/carcin/bgi047
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
26/6/1091    most recent
bgi047v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by de Moura Espíndola, R.
Right arrow Articles by Moreno, F. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Moura Espíndola, R.
Right arrow Articles by Moreno, F. S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis vol.26 no.6 © Oxford University Press 2005; all rights reserved.

Geranylgeraniol and ß-ionone inhibit hepatic preneoplastic lesions, cell proliferation, total plasma cholesterol and DNA damage during the initial phases of hepatocarcinogenesis, but only the former inhibits NF-{kappa}B activation

Roseli de Moura Espíndola, Rogério Pietro Mazzantini, Thomas Prates Ong, Aline de Conti, Renato Heidor and Fernando Salvador Moreno *

Laboratory of Diet, Nutrition and Cancer, Department of Food and Experimental Nutrition, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP, Brazil

* To whom correspondence should be addressed: Departamento de Alimentos e Nutrição Experimental, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, Bloco 14, Av. Prof. Lineu Prestes 580, 05508-900, São Paulo, SP, Brazil. Tel: 55 11 3091 3630; Fax: 55 11 3815 4410; Email: RMORENO{at}USP.BR

Chemopreventive activities of the isoprenoids geranylgeraniol (GGO) and ß-ionone (BI) were evaluated during initial phases of hepatocarcinogenesis. Rats received 8 or 16 mg/100 g body wt GGO (GGO8 and GGO16 groups) or BI (BI8 and BI16 groups), or only corn oil (CO group, controls) daily for 7 weeks. Incidence (%) and the mean number of visible hepatocyte nodules/animal were inhibited in the GGO8 (64% and 21 ± 40), GGO16 (33% and 3 ± 5), BI8 (50% and 13 ± 34) and BI16 (42% and 9 ± 19) groups compared with the CO group (100% and 34 ± 51) (P < 0.05, except for the GGO8 group). Number/cm2 liver section, mean area (mm2) and % liver section area occupied by persistent hepatic placental glutathione S-transferase positive preneoplastic lesions (PNL) were reduced in the GGO8 (11 ± 9; 0.26 ± 0.35; 2.7 ± 3.0), GGO16 (6 ± 6; 0.18 ± 0.16; 0.9 ± 0.9), BI8 (9 ± 5; 0.13 ± 0.20; 1.1 ± 1.2) and BI16 (8 ± 6; 0.08 ± 0.09; 0.6 ± 0.4) groups compared with the CO group (26 ± 18; 0.29 ± 0.34; 7.0 ± 5.5) (P < 0.05). GGO16 and BI16 groups showed smaller visible hepatocyte nodules, reduced PNL cell proliferation and total plasma cholesterol levels compared with the CO group (P < 0.05), but did not show any differences (P > 0.05) in PNL apoptosis. DNA damage expressed as comet length (µm) was reduced in the GGO8 (96.7 ± 1.5), GGO16 (94.2 ± 1.5), BI8 (97.1 ± 1.1) and BI16 (95.1 ± 1.5) groups compared with the CO group (102.1 ± 1.7) (P < 0.05). In comparison with normal animals, the CO group animals showed increased (P < 0.05) nuclear levels of nuclear factor kappa B (NF-{kappa}B) p65 subunit in hepatic cells, which were decreased (P < 0.05) in the GGO16 group animals. Anticarcinogenic actions of these isoprenoids seem to follow a dose–response relationship. Results indicate that GGO and BI could be represented as promising chemopreventive agents against hepatocarcinogenesis. Inhibition of cell proliferation and DNA damage seems to be important for the anticarcinogenic actions of isoprenoids, while the inhibition of NF-{kappa}B activation seems to be specifically related to GGO actions.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
N. B. Janakiram, I. Cooma, A. Mohammed, V. E. Steele, and C. V. Rao
-Ionone inhibits colonic aberrant crypt foci formation in rats, suppresses cell growth, and induces retinoid X receptor-{alpha} in human colon cancer cells
Mol. Cancer Ther., January 1, 2008; 7(1): 181 - 190.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
T. P. Ong, R. Heidor, A. de Conti, M. L. Z. Dagli, and F. S. Moreno
Farnesol and geraniol chemopreventive activities during the initial phases of hepatocarcinogenesis involve similar actions on cell proliferation and DNA damage, but distinct actions on apoptosis, plasma cholesterol and HMGCoA reductase
Carcinogenesis, June 1, 2006; 27(6): 1194 - 1203.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
E. M. de Almeida Vasconcelos Fonseca, C. E. A. Chagas, R. P. Mazzantini, R. Heidor, T. P. Ong, and F. S. Moreno
All-trans and 9-cis retinoic acids, retinol and {beta}-carotene chemopreventive activities during the initial phases of hepatocarcinogenesis involve distinct actions on glutathione S-transferase positive preneoplastic lesions remodeling and DNA damage
Carcinogenesis, November 1, 2005; 26(11): 1940 - 1946.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Ueno, D. Aoki, F. Kubo, K. Hiwatashi, K. Matsushita, T. Oyama, I. Maruyama, and T. Aikou
Roxithromycin Inhibits Constitutive Activation of Nuclear Factor {kappa}B by Diminishing Oxidative Stress in a Rat Model of Hepatocellular Carcinoma
Clin. Cancer Res., August 1, 2005; 11(15): 5645 - 5650.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.